Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% – Time to Sell?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell 3.7% during mid-day trading on Wednesday . The company traded as low as $13.71 and last traded at $14.65. 1,371,627 shares changed hands during trading, an increase of 16% from the average session volume of 1,180,047 shares. The stock had previously closed at $15.21.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Sunday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Price Performance

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average of $0.30 and a 200-day moving average of $0.27. The firm has a market capitalization of $2.75 billion, a P/E ratio of -0.28 and a beta of 2.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. On average, sell-side analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.